Covishield Vaccine Row: Following AstraZeneca's acknowledgment of a rare side effect associated with its COVID-19 vaccine, known as Covishield in India, the UK pharmaceutical giant extended sympathy to those impacted. Reaffirming its dedication to patient safety amidst concerns about potential rare side effects, AstraZeneca emphasised the vaccine's overall safety profile. The company underscored the stringent standards of regulatory authorities to ensure the safe use of medicines, including vaccines. AstraZeneca highlighted the extensive clinical trial data and real-world evidence consistently supporting the safety and efficacy of the vaccine.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.